Admedus announces the U.S. launch of a new version of its CardioCel regenerative bioscaffold for vascular repair.
Admedus (ASX:AHZ) announced the U.S. launch of a new CardioCel bioscaffold designed for vascular repairs.
AngioDynamics wants a federal court to enforce its $160 million judgment against erstwhile partner Biolitec AG and its CEO over an alleged scheme to evade U.S legal jurisdiction.
Saphena Medical, which is developing a device to harvest veins for coronary artery bypass grafting, is almost halfway toward raising $3 million in new funding.
Stealthy Saphena Medical reported raising close to half of a $3 million planned offering toward development of a device designed to harvest veins for coronary artery bypass grafting.
The West Bridgewater, Mass.-based startup disclosed in a recent SEC filing that it has pulled in nearly $1.27 million so far, through the sale of Series B preferred stock.
A federal appeals court issues a pair of wins to AngioDynamics in its long-running dispute with former partner Biolitec, including some $160 million in fines, but remands a portion of the case to cap the penalties.
Veniti, armed with $17 million in new financing, moves forward with more testing and an international launch of its Vici venous stent system.
Veniti said it nailed down a $17 million Series C financing it plans to use to advance testing and commercialization of its Vici venous stent system.
AngioDynamics inks a deal to invest in EmboMedics and its ResoSphere resorbable embolic microsphere technology, with a possible acquisition on the table.
A labeling miscue prompts Covidien to recall 2 models of its Trellis clot-busting infusion device.
UPDATED Feb. 12, 2015, with new information from Medtronic.